Ingram Micro to Replace Pacira in S&P SmallCap 600 Amid Viatris Deal
S&P Dow Jones Indices announced Ingram Micro (INGM) will replace Pacira BioSciences (PCRX) in the S&P SmallCap 600 on November 17, 2026, due to Pacira's pending acquisition by Viatris for $1.65 billion. Ingram Micro reported Q3 net sales of $15.2 billion, up 20.8% YoY, and net income of $131.1 million, up 31.8%.
How this was made
The 30-second read
Why it matters
The change will trigger passive fund rebalancing, creating buying pressure for Ingram Micro and selling pressure for Pacira, while Viatris remains the deal driver.
Market read
Index rebalancing creates short‑term trading opportunities for the three companies involved.
What to watch
Potential antitrust or financing delays in the Viatris‑Pacira deal could keep Pacira listed longer, affecting timing.
Background
S&P Dow Jones announced a composition change to the SmallCap 600, swapping Ingram Micro for Pacira as Viatris moves to acquire Pacira.
Ticker impact
Ingram Micro will replace Pacira in the S&P SmallCap 600 on Nov 17, adding index exposure.
likely upward pressure as index funds buy shares
Index inclusion drives passive buying and visibility.
Pacira is being removed from the S&P SmallCap 600 as it is being acquired by Viatris.
likely downward pressure as index funds sell and acquisition uncertainty persists
Index removal forces selling; acquisition adds execution risk.
Viatris' pending $1.65 B acquisition of Pacira creates the vacancy that triggers the index change.
minimal immediate impact; price may stay flat pending deal close
Acquisition already announced; index change is the headline event.
Market effects
IT sector gains a small‑cap weight; health‑care loses a small‑cap weight in the S&P SmallCap 600.
U.S. small‑cap market sees modest rebalancing; no broader regional effect.
Limited to U.S. index funds; negligible global impact.
Counterpoint
Index inclusion may be short‑lived if the acquisition closes quickly, reducing the benefit to Ingram Micro.
Key entities
- CompanyIngram Micro
NYSE‑listed IT distributor added to the S&P SmallCap 600.
- CompanyPacira BioSciences
Nasdaq‑listed health‑care firm being removed from the index.
- CompanyViatris
Pharma company acquiring Pacira for $1.65 B.
